Stocks of Novo Nordisk ADR (NYSE:NVO) traded higher last session on Wall Street, down -0.88% to $62.08.
NVO stock price is now -16.92% away from the 50-day moving average and -40.01% away from the 200-day moving average. The market capitalization of the company currently stands at $208.85B.
With the price target maintained at $64, BMO Capital Markets recently Downgraded its rating from Outperform to Market Perform for Novo Nordisk ADR (NYSE: NVO). , while ‘Stifel’ rates the stock as ‘Hold’
A total of 0.01% of the company’s stock is owned by insiders.
During the past 12 months, Novo Nordisk ADR has had a low of $57.00 and a high of $148.15. As of last week, the company has a debt-to-equity ratio of 0.72, a current ratio of 0.74, and a quick ratio of 0.55. According to the stock market information, the enterprise value for the company is $352176275456, which is based on a 18.91 price-to-earnings ratio, a 0.96 price-to-earnings-growth ratio, and a beta of 0.67. The fifty day moving average price for NVO is $74.7266 and a two-hundred day moving average price translates $103.4826 for the stock.
The latest earnings results from Novo Nordisk ADR (NYSE: NVO) was released for 2024-12-31. The net profit margin was 34.81% and return on equity was 82.03% for NVO. The company reported revenue of $12.26 billion for the quarter, compared to $9.53 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 28.71 percent. For the current quarter, analysts expect NVO to generate $77.81B in revenue.
